10% discount using “BOX10” code for order above $499 + Free Shipping
A-Ret 0.1% Gel 1 Aldactone 3 Allegra 2 Allegra M 1 Antiflu 75 2 Assurans 1 Asthalin respiratory solution 1 Augmentin 3 Azicip 250 (Zpac) 1 Azicip 500 (Zpac) 1 Azipro 250 (Zpac) 1 Azipro 500 (Zpac) 1 Bactrim d.s. 1 Balila 1 Belustine 40 1 Betaloc 50 1 Biltee 1 Bimat 0.03% Sterile Drops 1 Budecort 4 Careprost 0.03% Sterile Drops 1 Caverta 3 Cefix 1 Cenforce 6 Cenforce D 1 Cenforce FM 1 Cenforce Professional 1 Cialis 2 Cipmolnu 200 1 Cipmox 2 Claribid 250 1 Claribid 500 1 Climax Spray 1 Covilife 4 Covilife cream 1 Covilife MBD 1 Dabur Shilajit Gold Capsules 1 DOXENORM – LBX 1 DOXT – SL 1 Duprost 1 Duralast 1 Duratia 4 Dutas 1 Efil 3 Eltroxin 6 Emeset 2 Falcigo 2 Famcimac 500 1 Febucip 80 1 Febutec 40 1 Fildena 5 Fildena CT 1 Fildena Professional 1 Fildena Super Active 1 Fildena XXX 1 Floxip 1 Fluka 1 Fluvir (Tamiflu) 1 Fluvoxin 1 Glez 1 HealthVit 1 Imiquad Cream 1 Ipca – Hydroxychloroquine 2 Ivanorm 3 Iverheal 2 Iverheal 3 1 Iverjohn 1 Ivrea 1 Ivrea 1 1 John Lee – Ivermectin 2 Kamagra 2 Kamagra Oral Jelly 1 Laretol 1 Larinate 1 Levoflox 3 Levoquin 2 Low Dose Naltrexone (LDN) 3 LQuin 3 Lumigan 0.1% Sterile Drops 1 Lupimeb 1 Mebex 2 Medrol 3 Megalis 2 Methycobal injection (Vitamin B12) 1 Mirago 1 Modula 1 MONONATE DS 1 MONONATE SP 1 Montair 1 Montair FX 1 Movfor 200 1 Naprosyn 250 1 Naprosyn 500 1 Nervigesic 1 Netazox 500 1 Niclosig 1 Nizonide 500 1 Norsunate 2 Olmecip 1 Olmecip AM (Benicar) 1 Olmecip H (Benicar HCT) 1 Olmecip H 40 (Benicar) 1 Olmecip Trio (Benicar) 1 Omlecip 1 Omnacortil 4 Opsutan 1 Orokinase  Tablet 1 P-Force 1 Panacure 150 Tablet 1 Penegra 2 Pirfenex 200 1 Pirfenex 400 1 Predmet 3 Primovir 1 Radinate 1 Retina Ac Gel 1 Retina-A 0.025% Cream 1 Retina-A 0.04% Gel 1 Retina-A 0.05% Cream 1 Retina-A 0.1% Gel 1 Ridsunate 3 Rupanex 1 Rupanex – M 1 Rybelsus 3 Slim Trim Active 2 Stephonex 500 1 Super Kamagra 1 Symbicort Turbuhaler 3 T bact 1 Tadact 2 Tadaflo 3 Tadora 1 Tamodex 20 1 Tazzle 3 Tentex Royal Capsules 1 UPRISE-D3 1 Valcivir 2 Valif 1 Vidalista 6 Vidalista Black 1 Vidalista CT 1 Vidalista Professional 1 Vilitra 4 Wormentel 4 Zinconia – 50 1 Zocon DT 1

FDA-approved label information

Reproduced from the FDA Structured Product Label via the openFDA API. Label version: October 7, 2025.

Status
Human Prescription Drug
Brand names
Silodosin
Route
Oral
Drug class
alpha-Adrenergic Blocker [EPC]

Description

11 DESCRIPTION Silodosin capsule is a selective antagonist of alpha-1 adrenoreceptors. The chemical name of silodosin is 1-(3-Hydroxypropyl)-5-[(2 R )-2-({2-[2-(2,2,2-trifluoroethoxy)phenoxy]ethyl}amino) propyl]-2,3-dihydro-1 H -indole-7-carboxamide and the molecular formula is C 25 H 32 F 3 N 3 O 4 with a molecular weight of 495.53. The structural formula of silodosin is: Silodosin is a white to pale yellowish white powder that melts at approximately 105°C to 109°C. It is freely soluble in acetic acid, freely soluble in alcohol, and insoluble in water. Each Silodosin 8 mg capsule for oral administration contains 8 mg silodosin, and the following inactive ingredients: magnesium stearate, mannitol and sodium lauryl sulfate. The size #1 hard gelatin capsules contain gelatin, sodium lauryl sulfate and titanium dioxide. The capsules are printed with edible ink containing FD&C Blue No. 2 Aluminum Lake, propylene glycol, shellac, titanium dioxide and yellow iron oxide. Each Silodosin 4 mg capsule for oral administration contains 4 mg silodosin, and the following inactive ingredients: magnesium stearate, mannitol and sodium lauryl sulfate. The size #3 hard gelatin capsules contain gelatin, sodium lauryl sulfate and titanium dioxide. The capsules are printed with edible ink containing propylene glycol, shellac and yellow iron oxide. Silodosin

Indications and usage

1 INDICATIONS AND USAGE Silodosin capsules, an alpha-1 adrenergic receptor antagonist, is indicated for the treatment of the signs and symptoms of benign prostatic hyperplasia (BPH). Silodosin capsule is not indicated for the treatment of hypertension. ( 1 ) Silodosin capsule, a selective alpha-1 adrenergic receptor antagonist, is indicated for the treatment of the signs and symptoms of benign prostatic hyperplasia (BPH) [see CLINICAL STUDIES ( 14 )] . Silodosin capsule is not indicated for the treatment of hypertension.

Contraindications

4 CONTRAINDICATIONS Patients with severe renal impairment [Creatinine Clearance (CCr < 30 mL/min)]. ( 4 ) Patients with severe hepatic impairment (Child-Pugh score ≥ 10). ( 4 ) Concomitant administration with strong Cytochrome P450 3A4 (CYP3A4) inhibitors (e.g., ketoconazole, clarithromycin, itraconazole, ritonavir). ( 4 ) Patients with a history of hypersensitivity to silodosin or any of the ingredients of silodosin capsules. ( 4 ) Severe renal impairment (CCr < 30 mL/min) Severe hepatic impairment (Child-Pugh score ≥ 10) Concomitant administration with strong Cytochrome P450 3A4 (CYP3A4) inhibitors (e.g., ketoconazole, clarithromycin, itraconazole, ritonavir) [see DRUG INTERACTIONS ( 7.1 )] Patients with a history of hypersensitivity to silodosin or any of the ingredients of silodosin capsules [see ADVERSE REACTIONS ( 6.2 ) and DESCRIPTION ( 11 )]

Warnings and cautions

5 WARNINGS AND PRECAUTIONS Postural hypotension, with or without symptoms (e.g., dizziness), may develop when beginning silodosin treatment. ( 5.1 ) In patients with moderate renal impairment, silodosin dose should be reduced to 4 mg once daily. ( 5.2 ) Silodosin should not be used in combination with other alpha-blockers. ( 5.5 ) Examine patients thought to have BPH prior to starting therapy with silodosin to rule out the presence of carcinoma of the prostate. ( 5.6 ) Inform patients planning cataract surgery to notify their ophthalmologist that they are taking silodosin because of the possibility of Intraoperative Floppy Iris Syndrome (IFIS). ( 5.7 ) 5.1 Orthostatic Effects Postural hypotension, with or without symptoms (e.g., dizziness) may develop when beginning silodosin treatment. As with other alpha-blockers, there is potential for syncope. Patients should be cautioned about driving, operating machinery, or performing hazardous tasks when initiating therapy [ see ADVERSE REACTIONS ( 6 ), USE IN SPECIFIC POPULATIONS ( 8.5 ), CLINICAL PHARMACOLOGY ( 12.2 ), and PATIENT COUNSELING INFORMATION ( 17 ) ] . 5.2 Renal Impairment In a clinical pharmacology study, plasma concentrations (AUC and C max ) of silodosin were approximately three times higher in subjects with moderate renal impairment compared with subjects with normal renal function, while half-lives of silodosin doubled in duration. The dose of silodosin should be reduced to 4 mg in patients with moderate renal impairment. Exercise caution and monitor such patients for adverse events [see USE IN SPECIFIC POPULATIONS ( 8.6 ) and CLINICAL PHARMACOLOGY ( 12.3 )] . Silodosin is contraindicated in patients with severe renal impairment [see CONTRAINDICATIONS ( 4 )]. 5.3 Hepatic Impairment Silodosin has not been tested in patients with severe hepatic impairment, and therefore, should not be prescribed to such patients [see CONTRAINDICATIONS ( 4 ), USE IN SPECIFIC POPULATIONS ( 8.7 ) and CLINICAL PHARMACOLOGY ( 12.3 )] . 5.4 Pharmacokinetic Drug-Drug Interactions In a drug interaction study, co-administration of a single 8 mg dose of silodosin with 400 mg ketoconazole, a strong CYP3A4 inhibitor, caused a 3.8-fold increase in maximum plasma silodosin concentrations and 3.2-fold increase in silodosin exposure (i.e., AUC). Concomitant use of ketoconazole or other strong CYP3A4 inhibitors (e.g., itraconazole, clarithromycin, ritonavir) is therefore contraindicated [see DRUG INTERACTIONS ( 7.1 )]. 5.5 Pharmacodynamic Drug-Drug Interactions The pharmacodynamic interactions between silodosin and other alpha-blockers have not been determined. However, interactions may be expected, and silodosin should not be used in combination with other alpha-blockers [see DRUG INTERACTIONS ( 7.3 )]. A specific pharmacodynamic interaction study between silodosin and antihypertensive agents has not been performed. However, patients in the Phase 3 clinical studies taking concomitant antihypertensive medications with silodosin did not experience a significant increase in the incidence of syncope, dizziness, or orthostasis. Nevertheless, exercise caution during concomitant use with antihypertensives and monitor patients for possible adverse events [see ADVERSE REACTIONS ( 6.1 ) and DRUG INTERACTIONS ( 7.6 )]. Caution is also advised when alpha-adrenergic blocking agents including silodosin are co-administered with PDE5 inhibitors. Alpha-adrenergic blockers and PDE5 inhibitors are both vasodilators that can lower blood pressure. Concomitant use of these two drug classes can potentially cause symptomatic hypotension [see DRUG INTERACTIONS ( 7.5 )]. 5.6 Carcinoma of the Prostate Carcinoma of the prostate and BPH cause many of the same symptoms. These two diseases frequently co-exist. Therefore, patients thought to have BPH should be examined prior to starting therapy with silodosin to rule out the presence of carcinoma of the prostate. 5.7 Intraoperative Floppy Iris Syndrome Intraoperative Floppy Iris Syndrome has been observed during cataract surgery in some patients on alpha-1 blockers or previously treated with alpha-1 blockers. This variant of small pupil syndrome is characterized by the combination of a flaccid iris that billows in response to intraoperative irrigation currents; progressive intraoperative miosis despite preoperative dilation with standard mydriatic drugs; and potential prolapse of the iris toward the phacoemulsification incisions. Patients planning cataract surgery should be told to inform their ophthalmologist that they are taking silodosin [see ADVERSE REACTIONS ( 6.1 )]. 5.8 Laboratory Test Interactions No laboratory test interactions were observed during clinical evaluations. Treatment with silodosin for up to 52 weeks had no significant effect on prostate-specific antigen (PSA).

Adverse reactions

6 ADVERSE REACTIONS Most common adverse reactions (incidence ≥ 2%) are retrograde ejaculation, dizziness, diarrhea, orthostatic hypotension, headache, nasopharyngitis, and nasal congestion. ( 6 ) To report SUSPECTED ADVERSE REACTIONS, contact Lupin Pharmaceuticals, Inc. at 1-800-399-2561 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice. In U.S. clinical trials, 897 patients with BPH were exposed to 8 mg silodosin daily. This includes 486 patients exposed for 6 months and 168 patients exposed for 1 year. The population was 44 years to 87 years of age, and predominantly Caucasian. Of these patients, 42.8% were 65 years of age or older and 10.7% were 75 years of age or older. In double-blind, placebo controlled, 12-week clinical trials, 466 patients were administered silodosin and 457 patients were administered placebo. At least one treatment-emergent adverse reaction was reported by 55.2% of silodosin treated patients (36.8% for placebo treated). The majority (72.1%) of adverse reactions for the silodosin treated patients (59.8% for placebo treated) were qualified by the investigator as mild. A total of 6.4% of silodosin treated patients (2.2% for placebo treated) discontinued therapy due to an adverse reaction (treatment-emergent), the most common reaction being retrograde ejaculation (2.8%) for silodosin treated patients. Retrograde ejaculation is reversible upon discontinuation of treatment. Adverse Reactions Observed in at Least 2% of Patients: The incidence of treatment-emergent adverse reactions listed in the following table were derived from two 12-week, multicenter, double-blind, placebo-controlled clinical studies of silodosin 8 mg daily in BPH patients. Adverse reactions that occurred in at least 2% of patients treated with silodosin and more frequently than with placebo are shown in Table 1. Table 1: Adverse Reactions Occurring in > 2% of Patients in 12-week, Placebo-Controlled Clinical Trials Adverse Reactions Silodosin N = 466 n (%) Placebo N = 457 n (%) Retrograde Ejaculation 131 (28.1) 4 (0.9) Dizziness 15 (3.2) 5 (1.1) Diarrhea 12 (2.6) 6 (1.3) Orthostatic Hypotension 12 (2.6) 7 (1.5) Headache 11 (2.4) 4 (0.9) Nasopharyngitis 11 (2.4) 10 (2.2) Nasal Congestion 10 (2.1) 1 (0.2) In the two 12-week, placebo-controlled clinical trials, the following adverse events were reported by between 1% and 2% of patients receiving silodosin and occurred more frequently than with placebo: insomnia, PSA increased, sinusitis, abdominal pain, asthenia, and rhinorrhea. One case of syncope in a patient taking prazosin concomitantly and one case of priapism were reported in the silodosin treatment group. In a 9-month open-label safety study of silodosin, one case of Intraoperative Floppy Iris Syndrome (IFIS) was reported. 6.2 Postmarketing Experience The following adverse reactions have been identified during post approval use of silodosin. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure: Skin and Subcutaneous Tissue Disorders Toxic skin eruption, purpura, skin rash, pruritus, and urticaria Hepatobiliary Disorders J aundice, impaired hepatic function associated with increased transaminase values Immune System Disorders Allergic-type reactions, not limited to skin reactions including swollen tongue and pharyngeal edema resulting in serious outcomes

Drug interactions

7 DRUG INTERACTIONS Strong P-glycoprotein inhibitors (e.g., cyclosporine): Co-administration may increase plasma silodosin concentration. Concomitant use is not recommended. ( 7.2 ) Alpha-blockers: Interactions involving concomitant use have not been determined. However, interactions are expected and concomitant use is not recommended. ( 7.3 ) Concomitant use of PDE5 inhibitors with alpha-blockers including silodosin can potentially cause symptomatic hypotension. ( 5.5 , 7.5 ) 7.1 Moderate and Strong CYP3A4 Inhibitors In a clinical metabolic inhibition study, a 3.8-fold increase in silodosin maximum plasma concentrations and 3.2-fold increase in silodosin exposure were observed with concurrent administration of a strong CYP3A4 inhibitor, 400 mg ketoconazole. Use of strong CYP3A4 inhibitors such as itraconazole or ritonavir may cause plasma concentrations of silodosin to increase. Concomitant administration of strong CYP3A4 inhibitors and silodosin is contraindicated [see CONTRAINDICATIONS ( 4 ), WARNINGS AND PRECAUTIONS ( 5.4 ) and CLINICAL PHARMACOLOGY ( 12.3 )]. The effect of moderate CYP3A4 inhibitors on the pharmacokinetics of silodosin has not been evaluated. Concomitant administration with moderate CYP3A4 inhibitors (e.g., diltiazem, erythromycin, verapamil) may increase concentration of silodosin. Exercise caution and monitor patients for adverse events when co-administering silodosin with moderate CYP3A4 inhibitors. 7.2 Strong P-glycoprotein (P-gp) Inhibitors In vitro studies indicated that silodosin is a P-gp substrate. Ketoconazole, a CYP3A4 inhibitor that also inhibits P-gp, caused significant increase in exposure to silodosin. Inhibition of P-gp may lead to increased silodosin concentration. Silodosin is therefore not recommended in patients taking strong P-gp inhibitors such as cyclosporine [see CLINICAL PHARMACOLOGY ( 12.3 ) ]. 7.3 Alpha-Blockers The pharmacodynamic interactions between silodosin and other alpha-blockers have not been determined. However, interactions may be expected, and silodosin should not be used in combination with other alpha-blockers [see WARNINGS AND PRECAUTIONS ( 5.5 )] . 7.4 Digoxin The effect of co-administration of silodosin and digoxin 0.25 mg/day for 7 days was evaluated in a clinical trial in 16 healthy males, aged 18 years to 45 years. Concomitant administration of silodosin and digoxin did not significantly alter the steady state pharmacokinetics of digoxin. No dose adjustment is required. 7.5 PDE5 Inhibitors Co-administration of silodosin with a single dose of 100 mg sildenafil or 20 mg tadalafil was evaluated in a placebo-controlled clinical study that included 24 healthy male subjects, 45 years to 78 years of age. Orthostatic vital signs were monitored in the 12-hour period following concomitant dosing. During this period, the total number of positive orthostatic test results was greater in the group receiving silodosin plus a PDE5 inhibitor compared with silodosin alone. No events of symptomatic orthostasis or dizziness were reported in subjects receiving silodosin with a PDE5 inhibitor. 7.6 Other Concomitant Drug Therapy Antihypertensives The pharmacodynamic interactions between silodosin and antihypertensives have not been rigorously investigated in a clinical study. However, approximately one-third of the patients in clinical studies used concomitant antihypertensive medications with silodosin. The incidence of dizziness and orthostatic hypotension in these patients was higher than in the general silodosin population (4.6% versus 3.8% and 3.4% versus 3.2%, respectively). Exercise caution during concomitant use with antihypertensives and monitor patients for possible adverse events [see WARNINGS AND PRECAUTIONS ( 5.5 )]. Metabolic Interactions In vitro data indicate that silodosin does not have the potential to inhibit or induce cytochrome P450 enzyme systems. 7.7 Food Interactions The effect of a moderate fat, moderate calorie meal on silodosin pharmacokinetics was variable and decreased silodosin maximum plasma concentration (C max ) by approximately 18% to 43% and exposure (AUC) by 4% to 49% across three different studies. Safety and efficacy clinical trials for silodosin were always conducted in the presence of food intake. Patients should be instructed to take silodosin with a meal to reduce risk of adverse events [see CLINICAL PHARMACOLOGY ( 12.3 )].

Use in specific populations

8 USE IN SPECIFIC POPULATIONS Renal impairment: Dose adjustment in moderate disease ( 2.2 ). Contraindicated in severe renal disease. ( 4 ) Hepatic impairment: Contraindicated in severe disease. ( 4 ) 8.1 Pregnancy Risk Summary Silodosin is not indicated for use in females. 8.2 Lactation Silodosin is not indicated for use in females. 8.3 Females and Males of Reproductive Potential Infertility Males Possible effects on male fertility could be observed based on findings in rats at exposures that were at least two times higher than at the MRHD (based on AUC). These findings may be reversible, and the clinical relevance is unknown [see NONCLINICAL TOXICOLOGY (13.1)]. 8.4 Pediatric Use Silodosin is not indicated for use in pediatric patients. Safety and effectiveness in pediatric patients have not been established. 8.5 Geriatric Use In double-blind, placebo-controlled, 12-week clinical studies of silodosin, 259 (55.6%) were under 65 years of age, 207 (44.4%) patients were 65 years of age and over, while 60 (12.9%) patients were 75 years of age and over. Orthostatic hypotension was reported in 2.3% of silodosin patients < 65 years of age (1.2% for placebo), 2.9% of silodosin patients ≥ 65 years of age (1.9% for placebo), and 5.0% of patients ≥ 75 years of age (0% for placebo). There were otherwise no significant differences in safety or effectiveness between older and younger patients [see CLINICAL PHARMACOLOGY ( 12.3 )] . 8.6 Renal Impairment The effect of renal impairment on silodosin pharmacokinetics was evaluated in a single dose study of six male patients with moderate renal impairment and seven male subjects with normal renal function. Plasma concentrations of silodosin were approximately three times higher in subjects with moderate renal impairment compared with subjects with normal renal function. Silodosin should be reduced to 4 mg per day in patients with moderate renal impairment. Exercise caution and monitor patients for adverse events. Silodosin has not been studied in patients with severe renal impairment. Silodosin is contraindicated in patients with severe renal impairment [see CONTRAINDICATIONS ( 4 ), WARNINGS AND PRECAUTIONS ( 5.2 ) and CLINICAL PHARMACOLOGY ( 12.3 )]. 8.7 Hepatic Impairment In a study comparing nine male patients with moderate hepatic impairment (Child-Pugh scores 7 to 9), to nine healthy male subjects, the single dose pharmacokinetics of silodosin were not significantly altered in patients with hepatic impairment. No dosing adjustment is required in patients with mild or moderate hepatic impairment. Silodosin has not been studied in patients with severe hepatic impairment. Silodosin is contraindicated in patients with severe hepatic impairment [see CONTRAINDICATIONS ( 4 ), WARNINGS AND PRECAUTIONS ( 5.3 ) and CLINICAL PHARMACOLOGY ( 12.3 )].

Pregnancy

8.1 Pregnancy Risk Summary Silodosin is not indicated for use in females.

Paediatric use

8.4 Pediatric Use Silodosin is not indicated for use in pediatric patients. Safety and effectiveness in pediatric patients have not been established.

Overdosage

10 OVERDOSAGE Silodosin was evaluated at doses of up to 48 mg/day in healthy male subjects. The dose-limiting adverse event was postural hypotension. Should overdose of silodosin lead to hypotension, support of the cardiovascular system is of first importance. Restoration of blood pressure and normalization of heart rate may be accomplished by maintaining the patient in the supine position. If this measure is inadequate, administration of intravenous fluid should be considered. If necessary, vasopressors could be used, and renal function should be monitored and supported as needed. Dialysis is unlikely to be of significant benefit since silodosin is highly (97%) protein bound.

Source: US Food and Drug Administration, via the openFDA API. The FDA does not review, endorse or verify third-party reproductions of this data, and label information may have been updated since it was retrieved.
Read the current full label on DailyMed

FDA approval applies to the uses listed on the label. Approval status in your country may differ.

This glossary entry is general health information, not medical advice, not a diagnosis, and not a recommendation to use any medicine. Medicines described here may be prescription-only where you live. Always speak to a qualified doctor or pharmacist before starting, stopping, or changing any treatment.
Trustpilot logoTrustpilot
Good rating
TrustScore 3.7
1 reviews